Please login to the form below

VPAS

This page shows the latest VPAS news and features for those working in and with pharma, biotech and healthcare.

Europe responding to gene therapy challenge, but picture remains fragmented

The new framework will build on the new UK-wide pricing agreement, the Voluntary Scheme for Branded Medicines Pricing and Access ( VPAS), and is expected to go out to industry for

Latest news

NHS England’s medicines chief: stop ‘salami slicing’ and get faster market access

Dark's arrival coincided with the signing of a new five-year Voluntary Price and Access Scheme (VPAS), which caps NHS expenditure on medicines, but also allows NHS England to agree ... mindful of that, maintaining a tough bargaining position, even though
NHS Long-term Plan welcomed – but warnings on staff and overpromising

UK pharma industry response. The new Long-term Plan coincides with the launch of a new five year Voluntary Pricing and Access Scheme (VPAS) covering branded medicines in the UK. ... He also hailed the introduction of the VPAS, saying it “should see the
New ‘voluntary’ UK pricing deal caps growth, but promises faster uptake

Decades old PPRS name to go

More from news
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest Intelligence

Evolution or revolution: the latest review of NICE methods

What is not part of the review – because it’s a done deal as part of VPAS – is the basic cost- effectiveness threshold. ... Leela worked as an advisor to the Department of Health and Social Care on the 2019 Voluntary Scheme for Branded Medicines
The UK’s new medicines pricing deal – opportunities and risks for pharma

So what are the big differences between the 2014 PPRS and the 2019 VPAS? ... Overall VPAS covers more than 85% of all NHS spend on branded drugs.
The UK’s new five-year pricing agreement

The UK has a new five-year Voluntary Pricing and Access Scheme (VPAS) for branded medicines, which came into force on 1 January 2019.
Comment: the new UK pricing deal – welcome news, but lessons to be learned

Leslie Galloway, chairman of EMIG reflects on the new UK government-pharma industry pricing agreement

More from intelligence
Approximately 2 fully matching, plus 2 partially matching documents found.

Latest from PMHub

Volt Pharma Associates

VPA supports life sciences companies, investors and academic institutes in developing new products, technologies and innovative approaches. ... VPA’s aim is to solve our clients’ product research, development and commercialisation challenges so they

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

Virtual Engagement At Porterhouse: Reflections on the past few months: ...
July 2020: diversity and inclusion in clinical trials round-up: COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
Medical Device Clinical Trials 2020: In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...